4,901 trials
Healthy Adult Subjects · Healthy Elderly Subjects
Primary: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness — 2.16; 7.50; 6.71; 3.50 Units on a scale
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib — 1140; 1720 nanograms/milliliter (ng/mL)
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Time Tlast (AUC0-tlast) of Evacetrapib — 10700; 10500; 13200; 15800…
Advanced Solid Tumors
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) of PF-05082566 in Combination With MK-3475 — 0; 0; 0; 0 Participants
Lymphangioleiomyomatosis
Primary: Safety of Combination Therapy With Sirolimus and Hydroxychloroquine in LAM Patients — 2.27; 1.11; 0; 1.11 Percentage of adverse events
Healthy
Primary: Area Under the Concentration-time Curve of BI 695501 in Plasma Over the Time Interval From 0 to 1368 Hours (AUC0-1368) After Administration Via PFS and AI. — 2100; 2150…
Healthy Adult Immune Responses to Vaccine
Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of Evacetrapib (Fasted) — 14600; 14600 nanogram·hour/milliliter (ng·h/mL)
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib — 7700; 23600 nanogram * hour per milliliter (ng*h/mL)
Advanced Solid Tumors
Primary: Steady-state Serum Concentration of Dalotuzumab at 336 Hours (C336) After the First Maintenance Dose — 4.78; 7.48; 54.57; 33.00 μg/mL
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol — 71.7; 70.6 picogram per milliliter (pg/ml)
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Digoxin — 1.75; 2.15 nanograms/milliliter (ng/mL)
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Pravastatin — 142; 128 nanograms/milliliter (ng/mL)
Japanese Healthy Adult Male Participants
Primary: AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-536 — 6053.7; 6479.6 hour*nanogram per milliliter (h*ng/mL)
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of S-Warfarin — 132; 126 nanograms*hour/milliliter (ng*h/mL)